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ARTICLE OPEN
Oleoylethanolamide decreases frustration stress-induced
binge-like eating in female rats: a novel potential
treatment for binge eating disorder
Adele Romano1, Maria Vittoria Micioni Di Bonaventura 2, Cristina Anna Gallelli1, Justyna Barbara Koczwara1, Dorien Smeets1,
Maria Elena Giusepponi2, Marialuisa De Ceglia1, Marzia Friuli1, Emanuela Micioni Di Bonaventura2, Caterina Scuderi1,
Annabella Vitalone 1, Antonella Tramutola3, Fabio Altieri 3, Thomas A. Lutz4, Anna Maria Giudetti5, Tommaso Cassano 6,
Carlo Cifani 2 and Silvana Gaetani 1
Binge eating disorder (BED) is the most frequent eating disorder, for which current pharmacotherapies show poor response rates
and safety concerns, thus highlighting the need for novel treatment options. The lipid-derived messenger oleoylethanolamide
(OEA) acts as a satiety signal inhibiting food intake through the involvement of central noradrenergic and oxytocinergic neurons.
We investigated the anti-binge effects of OEA in a rat model of binge-like eating, in which, after cycles of intermittent food
restrictions/refeeding and palatable food consumptions, female rats show a binge-like intake of palatable food, following a 15-min
exposure to their sight and smell (“frustration stress”). Systemically administered OEA dose-dependently (2.5, 5, and 10mg kg−1)
prevented binge-like eating. This behavioral effect was associated with a decreased activation (measured by mapping the
expression of c-fos, an early gene widely used as a marker of cellular activation) of brain areas responding to stress (such as the
nucleus accumbens and amygdala) and to a stimulation of areas involved in the control of food intake, such as the VTA and the
PVN. These effects were paralleled, also, to the modulation of monoamine transmission in key brain areas involved in both
homeostatic and hedonic control of eating. In particular, a decreased dopaminergic response to stress was observed by measuring
dopamine extracellular concentrations in microdialysates from the nucleus accumbens shell, whereas an increased serotonergic
and noradrenergic tone was detected in tissue homogenates of selected brain areas. Finally, a decrease in corticotropin-releasing
factor (CRF) mRNA levels was induced by OEA in the central amygdala, while an increase in oxytocin mRNA levels was induced in
the PVN. The restoration of a normal oxytocin receptor density in the striatum paralleled the oxytocinergic stimulation produced by
OEA. In conclusion, we provide evidence suggesting that OEA might represent a novel potential pharmacological target for the
treatment of binge-like eating behavior.
Neuropsychopharmacology (2020) 0:1–11; https://doi.org/10.1038/s41386-020-0686-z
INTRODUCTION
Binge eating disorder (BED) is the most frequent eating disorder
occurring in 2–5% of the adult population, with a higher
prevalence among women than men [1–3]. BED is characterized
by uncontrollable and compulsive episodes of excessive con-
sumption of highly palatable food (HPF) accompanied by a strong
sense of loss of control, feeling of shame, guilt, disgust, and
anxiety. The combination of dieting and stress is a common
trigger for BED [4, 5], which shares a variety of commonalities with
drug addiction [6]. A large body of evidence suggests that the
neurobiological mechanisms of BED converge on the activation of
the mesocorticolimbic dopamine (DA) system [7, 8], as well as on
brain serotonin (5-HT) and noradrenaline (NA) signaling [9–12].
Lisdexamfetamine, a prodrug of d-amphetamine, is the first
medication approved for BED treatment in the United States that
acts primarily by enhancing brain dopaminergic and noradrener-
gic neurotransmission [13]. Its most common side effects include
insomnia, weight loss, and headache [14], and its highest limit
derives from serious adverse effects in patients suffering from
cardiomyopathies, which are quite frequent comorbidities [15, 16].
Furthermore, being a psychostimulant, there is a considerable risk
of abuse. Other treatments tested for BED lack sufficient efficacy,
and are complicated by high relapse rates and a wide range of
side effects [17, 18].
Several observations have been accumulated, suggesting that
the lipid-derived messenger oleoylethanolamide (OEA) might
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represent a better pharmacological target for the treatment of
BED [19–21]. OEA reduces food intake and body weight gain in
obese rodents and humans [20, 22], mainly through the
activation of peroxisome proliferator-activated receptor-alpha
[23], with a mechanism that appears behaviorally selective
[24, 25] and associated with the activation of key brain areas,
including the nucleus of the solitary tract, the area postrema
[26, 27], the tuberomammillar [28], and paraventricular (PVN) [29]
nuclei, where noradrenergic [30], histaminergic [31], and
oxytocinergic [32] neurons play a necessary role. Interestingly,
it has been demonstrated that OEA treatment is able to restore a
physiologic sensitivity to the rewarding properties of fat in diet-
induced obese mice [33], and it is able to exert anti-depressant-
like effect in different animal laboratory models [34, 35], by
regulating the level of both 5-HT and NA in the brain [36]. In this
study, we used a rat model of binge-like palatable food
consumption [37–41] to test the hypothesis that OEA might be
a novel target for BED treatment. In this model, young female
rats are subjected to three 8-day cycles (total 24 days) of
intermittent food restriction/refeeding (Fig. 1a). On the day of
the experiment (day 25), these rats show binge-like HPF
consumption after the exposure to a 15-min “frustration stress”,
consisting of the sight and smell of HPF placed out of reach
[42–46] (Supplementary Fig. S1B). We will refer in the text to
dietary-restricted (R) vs not-restricted (NR) rats and exposed-to-
stress (S) vs not-exposed-to stress (NS) rats (Fig. 1a). In this
model, we investigated the anti-binging acute effects of OEA
(2.5, 5, or 10 mg kg−1, i.p.) on HPF intake, and analyzed the
neurobiological bases of these effects by focusing on different
endpoints. These include the brain pattern of c-Fos expression,
DA extracellular release in the shell of the nucleus accumbens
(AcbSh), monoamine tissue concentrations/turnovers in selected
brain regions, corticotropin-releasing factor (CRF), and oxytocin
mRNA levels in the central amygdala (CeA) and PVN and, finally,
oxytocin receptor immunoreactivity in selected brain areas
(Fig. 1b). In all these neurochemical analyses, we focused our
attention on the stressed groups (R+ S vs NR+ S), comparing
the effects of OEA vs vehicle treatment. The rationale of this
choice is based on the observation that intermittent caloric
restriction is the predisposing condition that allows stress to act
as a trigger (R+ S), whereas the ad libitum feeding condition
represents the baseline control, in which stress is ineffective
(NR+ S), thus also providing the control for the stress effect
(Supplementary Fig. S1B).
MATERIALS AND METHODS
Binge eating model
One-hundred and eighty-four female Sprague Dawley rats
(Charles River, Italy), 200–225 g at the beginning of the
experiments, were housed under a 12-h light/dark cycle (lights
on at 8:00 a.m.), at constant temperature (20–22° C) and
humidity (45–55%), and with access to food and water ad
libitum for 2 weeks before the experiments. According to the
dietary schedule, the rats were given standard food pellets
(4RF18, Mucedola, 2.6 kcal/g) or HPF (3.63 kcal/g) consisting of a
paste prepared by mixing Nutella (Ferrero®) chocolate cream
(5.33 kcal/g; 56, 31, and 7% from carbohydrate, fat, and protein,
respectively), grounded food pellets (4RF18), and water in the
following w/w/w percent ratio: 52% Nutella, 33% food pellets,
and 15% water.
The procedure for binge eating induction was performed
according to our previous studies [37, 47, 48]. Briefly, two groups
of female rats were housed individually in metal cages (30 × 30 ×
30 cm) and exposed (or not exposed) for 24 days to three 8-day
cycles of intermittent food restriction (66% of chow intake on days
1–4 and free feeding on days 5–8 of each cycle), during which
they were given access to HPF for 2 h during the light cycle
between 10:00 a.m. and 12:00 a.m. (2 h after the onset of the light
cycle) on days 5–6 and 13–14 of the first two cycles (total of four
exposures). Although this intermittent caloric restriction caused
body weight fluctuations during the three cycles, on the test day,
similar body weights (S2 Supplementary results and Supplemen-
tary Fig. S1A) were detected in all rats.
On the test day (day 25), at 10 a.m., half of the rats in each
group were subjected to a 15-min frustration stress, consisting of
the exposure to HPF placed out of reach. During this 15-min
period, the rats could smell and see the HPF and repeatedly
attempted to reach it. The second half of rats in each group were
not exposed to the stress manipulation. Therefore, we will refer in
this paper to dietary restricted (R) vs non restricted (NR) rats and
exposed to stress (S) vs non exposed to stress (NS) rats. After 15
min of stress exposure, the HPF was placed inside the cage for all
rats. In accordance with our previous studies, binge eating
behavior occurred in R+ S rats (Supplementary Fig. S1B), as
demonstrated by the immediate and persistent consumption of a
larger amount of HPF within the first 15-min access, with respect
to the other groups (S2 Supplementary results). Vaginal smears
were collected at the end of the experiments to exclude from the
results rats in the estrous phase, since we previously observed that
binge eating does not occur during the estrous phase of female
rats [49, 50].
The experimental procedure is depicted in Fig. 1a. This
paradigm was used in four different experiments, in which the
consumption of the HPF was allowed for 120min, 60min, or
0 min, depending on the endpoints analyzed (Fig. 1b). All experi-
ments were carried out in accordance with the European directive
2010/63/UE governing animal welfare, and with the Italian
Ministry of Health guidelines for the care and use of laboratory
animals.
Experiment 1: effect of OEA on stress-induced binge eating
The first set of rats (N= 144) was divided into 16 groups (N= 9 per
group) in a 2 (history of intermittent food restriction: yes (R), no
(NR) rats) × 2 (stress during testing: yes (S), no (NS) rats) × 4 (OEA
dose: 0, 2.5, 5, and 10mg kg−1) factorial design, to evaluate the
behavioral effects of OEA during the test day. To this aim, OEA or
vehicle were administered 1 h before the access to HPF; rats were
exposed (or not exposed) to the 15-min frustration stress, and
once they had access to the HPF, the intake was measured at the
following time points (15, 30, 60, and 120min). The experimental
paradigm is depicted in Fig. 1b (EXP. 1). After testing, 29 rats
were excluded from statistical analyses because they were in the
estrous phase.
Experiment 2: effects of OEA on the pattern of c-Fos, oxytocin
receptor expression, and on monoamine turnover
Previous studies demonstrated that the effect of OEA on food
intake is paralleled by a selective induction of c-fos, an immediate
early gene widely used as a marker of cellular activation, at the
level of the hypothalamus (HYPO) and brainstem [26, 27, 29], key
regions involved in the control of feeding [51]. Here, we have
expanded those findings by examining the impact of OEA (10mg
kg−1) on the brain pattern of c-Fos immunostaining in response to
60min of HPF consumption in female rats with different diet
histories and exposed to acute stress (R+ S vs NR+ S, Fig. 1b, EXP.
2). In this experiment, we tested the effects of the highest dose
(OEA 10mg kg−1 i.p.), based on the observations made in EXP. 1.
Moreover, we evaluated whether the interaction between food
restriction and stress exposure is accompanied by alteration of
oxytocin receptor immunoreactivity in selected brain regions, and
whether OEA treatment is able to affect this endpoint.
As a further aim of this experiment (Fig. 1b, EXP. 2), we analyzed
the effects of OEA on tissue concentrations of monoamines (DA, 5-
HT, and NA) and their main metabolites in the principal neural
nodes that control different aspects of food intake in the brain.
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The immunohistochemistry experiment and monoamine ana-
lyses were performed according to our previous studies [27, 52].
The detailed protocols are described in the sections S1.1 of
Supplementary Materials and Methods.
Experiment 3: effects of OEA on DA transmission in the AcbSh
To investigate whether OEA would decrease the central dopami-
nergic response to appetitive/reinforcing stimuli, we performed
in vivo microdialysis experiment to evaluate DA extracellular
OEA decreases frustration stress-induced binge-like eating
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concentration at the level of the AcbSh in R+ S and NR+ S rats
(Fig. 1b, EXP. 3), according to the protocol used in our previous
study [53, 54]. To this aim, a new set of rats (N= 40) was divided
into R and NR groups, according to the protocol described for
EXP. 1, and underwent the procedure for microdialysis experi-
ment. The detailed protocol is described in the section S1.2 of
Supplementary Materials and Methods and in the legend of Fig. 3.
Experiment 4: effects of OEA on CRF and oxytocin mRNA
In situ hybridization was performed in brain slices obtained from
R+ S and NR+ S rats according to the protocol reported in our
previous studies [26, 29, 55]. The detailed protocol is described in
the section S1.3 of Supplementary Materials and Methods.
Statistical analyses
Statistical analysis is described in the section S1.4 of Supplemen-
tary Information.
RESULTS
OEA treatment selectively prevented binge-like eating in a dose-
dependent manner
We found that acute treatment with OEA, systemically adminis-
tered to rats 1 h before giving access to HPF (Fig. 1b, EXP. 1),
selectively prevented binge-like eating of R+ S rats (Fig. 1c),
without altering feeding behavior in the other experimental
groups (Fig. 1d–f). In particular, OEA decreased frustration stress-
induced HPF overconsumption in a dose- and time-dependent
manner, with the strongest and long-lasting effect observed at the
dosage of 10 mg kg−1 i.p. (Fig. 1c). The intermediate dose of OEA
(5 mg kg−1 i.p.) was effective only at the 15-min time point, while
the lowest dose of OEA was ineffective. The results obtained from
ANOVA showed a significant effect of treatment in the session
time 0–15min (Ftreatment= 29.763, df= 3/27, P < 0.001) and in
0–120 min (Ftreatment= 5.758, df= 3/27, P < 0.01). Significant dif-
ferences among groups evaluated by the post hoc analyses are
indicated in Fig. 1c.
OEA treatment affected the brain pattern of c-Fos expression in
bingeing rats
The semiquantitative analyses of immunostaining optical densities
revealed that the interaction between intermittent food restriction
and stress exposure induced an increase of c-Fos expression in the
nucleus accumbens (Acb), caudate putamen (CPu), amygdala
(AMY), and substantia nigra (SN) of bingeing rats (R+ S veh), with
respect to non-bingeing rats (NR+ S veh), and that OEA treatment
completely prevented such increase (Fig. 2c, d, f, h). Conversely, c-
Fos expression within the PVN, pedunculopontine nucleus (PP),
and ventral tegmental area (VTA) (Fig. 2e, g, i) was unchanged in
bingeing rats (R+ S veh), with respect to non-binging rats (NR+ S
veh), but significantly increased by OEA treatment (R+ S-OEA vs R
+ S veh), which induced a similar effect also in the AMY and PP of
NR+ S rats (Fig. 2f, g, respectively). No difference was observed
within the ventral pallidum nucleus among all rat groups (Fig. 2b).
The results from the two-way ANOVA analyses of c-Fos expression
are reported in Table S1; the results obtained from the post hoc
analyses are reported in Fig. 2.
OEA treatment affected monoaminergic system in bingeing rats
The results obtained from two-way ANOVA analyses are reported
in Table S2, while the results from the post hoc analyses (Tukey’s
test) are reported in Table 1. Overall, the results (Table 1) revealed
that OEA treatment affected mainly monoaminergic tissue
concentration/turnover in bingeing rats, rather than in NR+ S
rats. In fact, in NR+ S rats, the effects of OEA treatment included
only an increase in NA and DA concentration within the HYPO and
VTA, respectively, and an increase of 5-HT turnover in the Acb.
Analyzing the results obtained from vehicle- administered rats,
bingeing rats (R+ S veh) showed an increased DA turnover in the
medial prefrontal cortex (mPFC) and AMY, as well as increased 5-
HT turnover and 5-HT tissue concentration in the AMY and HYPO,
respectively, as compared with non-bingeing rats (NR+ S veh).
The increased turnovers observed in the mPFC and AMY of
bingeing rats resulted in complete prevention by OEA treatment,
which increased DA and 5-HT concentrations in the mPFC. The
latter effect was accompanied by a decrease of 5-HT turnover in
the mPFC of R+ S OEA rats, with respect to their vehicle-treated
controls. DA tissue concentrations were affected by OEA
treatment also in Acb (where it decreased) and VTA (where it
increased) of R+ S rats, without producing any effect on DA
turnover. Similarly, OEA administration to R+ S rats caused a
marked increase of 5-HT tissue concentrations in Acb, hippocam-
pus (HIPP), VTA, and locus ceruleus (LC), without affecting 5-HT
turnover in these areas. Finally, OEA treatment caused a significant
increase of NA concentration in the CPu, HYPO, VTA, and LC.
OEA treatment dampened AcbSh DA release induced by stress
exposure or amphetamine challenge
In agreement with previous reports [56–59], in both rat groups
treated with vehicle, dialysate DA levels significantly exceeded the
basal values in response to stress exposure or to amphetamine
challenge, with no change induced by HPF consumption (Fig. 3a,
b). The first increase in response to stress exposure was transitory
(15 min) and reached 292 and 194% in NR+ S veh and R+ S
vehicle rats, respectively; the second increase was long-lasting
(about 90min) and reached maximum values of 764% and 638%,
in non-bingeing and bingeing vehicle-treated rats, respectively.
OEA administration did not alter DA basal levels in either
Fig. 1 OEA treatment selectively prevented binge-like eating in a dose-dependent manner. a Female rats were exposed (restricted rats, R)
or not exposed (non restricted, NR) to three 8-day cycles of intermittent food restriction (66% of chow intake), occurring on days 1–4, and free-
feeding condition allowed on days 5–8 of each cycle. During the ad libitum condition of days 5–6 and 13–14 of the first two cycles, both NR
and R rats were given access to HPF for 2 h during the light phase. On day 25, both R and NR rats were exposed (R+ S and NR+ S) or not
exposed (R+NS and NR+NS) to frustration stress. b EXP. 1: on test day (day 25), after the third cycle, both NR and R rats were administered
with vehicle (veh) or three different doses of OEA (2.5, 5, and 10mg kg−1, intraperitoneal injection (i.p.)). Forty-five minutes after treatments,
both NR and R rats were exposed (stressed: NR+ S and R+ S) or not exposed (non stressed: NR+NS and R+NS) to a 15-min stress
procedure. One hour after the respective treatments, rats were given free access to HPF for 120min, and food intake was monitored. EXP. 2:
NR+ S and R+ S rats were administered with veh or OEA (10mg kg−1 i.p.), and were allowed to consume the HPF only for 60min. At the end
of this procedure, rats were sacrificed, their brains immediately collected for immunohistochemical evaluation of the pattern of c-Fos
expression, oxytocin receptor expression, and HPLC analyses of monoamine turnover. EXP. 3: NR+ S and R+ S rats were administered with
veh or OEA (10mg kg−1, i.p.), and underwent brain microdialysis in the AcbSh for the analysis of DA extracellular levels (the detailed paradigm
of the microdialysis experiment is described in the legend of Fig. 3). EXP. 4: NR+ S and R+ S rats were administered with veh or OEA (10 mg
kg−1, i.p.), and immediately sacrificed at the end of the stress procedure. Their brains were collected for in situ hybridization analysis of CRF
and oxytocin mRNA. HPF intake (kcal kg−1) during the first 15min (left) and the total 120min (right) test session after vehicle (veh) or three
different doses of OEA (2.5, 5, and 10mg kg−1 i.p.) administration to R+ S (c, restricted+ stressed, N= 31), R+NS (d, restricted+ non stressed,
N= 28), NR+ S (e, non restricted+ stressed, N= 26), and NR+NS (f, non restricted+ non stressed, N= 30). Data are expressed as mean ±
SEM. **P < 0.01; ***P < 0.001 vs R+ S veh (Bonferroni’s test for multiple comparisons).
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Fig. 2 OEA treatment affected the brain pattern of c-Fos expression in bingeing rats. Representative photomicrographs (scale bar= 500 μm, a)
showing c-Fos immunostaining within the ventral pallidum (VP), nucleus accumbens (Acb), caudate putamen (CPu), paraventricular nucleus (PVN),
amygdala (AMY), pedunculopontine nucleus (PP), substantia nigra (SN), and ventral tegmental area (VTA) in brain slices collected from both NR+
S (non restricted+ stressed) and R+ S (restricted+ stressed) rats treated with either vehicle (veh) or OEA (10mg kg−1, i.p.) and sacrificed 120min
after treatment. Semiquantitative densitometric analysis of c-Fos expression within the VP (b), Acb (c), CPu (d), PVN (e), AMY (f), PP (g), SN (h), and
VTA (i) of NR+ S and R+ S rats treated with either veh or OEA (10mg kg−1, i.p.) and sacrificed 120min after treatment. Data are expressed as
mean ± SEM. *P < 0.05; ***P < 0.001 vs veh in the same diet regimen group; °P < 0.05; °°P < 0.01; °°°P < 0.001 vs NR+ S in the same treatment group
(Tukey’s post hoc test, N= 3).
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experimental groups, but significantly attenuated the increase in
DA efflux evoked by frustration stress and by amphetamine
challenge, independently from the history of caloric restriction
(Fig. 3a, b).
The results obtained by the two-way ANOVA for repeated
measures revealed a significant effect of time, treatment, and a
significant interaction between the two factors (R+ S: Ftime=
17.252, df= 18/234, P < 0.001, Ftreatment= 27.407, df= 1/13, P <
0.001, and Finteraction= 5.018, df= 18/234, P < 0.01; NR+ S: Ftime=
15.216, df= 18/324, P < 0.001, Ftreatment= 6.154, df= 1/18, P <
0.05, and Finteraction= 3.142, df= 18/324, P < 0.05). The results
obtained by post hoc tests are reported in Fig. 3a, b.
OEA treatment affected CRF and oxytocin mRNA levels in bingeing
rats
We previously demonstrated a crucial role of oxytocinergic
neurotransmission in mediating the hypophagic effect of OEA
[29], as well as the pivotal role played by CRF system in sustaining
binge eating behavior in the experimental model used in the
present study [47]. Since both oxytocin and CRF can be affected
by stress and food intake, we assessed the “pure” effects of OEA
on stress response without the potential impact of caloric
consumption, to evaluate whether the anti-bingeing effects of
OEA might be attributed to a reduced effect of stress exposure. To
this aim, we measured both CRF and oxytocin mRNA levels by
Table 1. Tissue monoamine concentrations (ngmg–1 of wet tissue) and monoamine turnover in selected brain areas.
NR + S rats R + S rats
VEH OEA VEH OEA
mPFC
DA 0.05 ± 0.01 0.05 ± 0.005 0.03 ± 0.002 0.06 ± 0.01
DOPAC+HVA/DA 3.07 ± 0.16 2.69 ± 0.52 4.48 ± 0.41 2.11 ± 0.19
NA 0.20 ± 0.03 0.20 ± 0.02 0.20 ± 0.02 0.19 ± 0.03
5HT 0.08 ± 0.01 0.09 ± 0.01 0.07 ± 0.01 0.14 ± 0.03
5HIAA/5HT 4.13 ± 0.67 3.54 ± 0.80 5.15 ± 1.11 2.44 ± 0.31
Acb
DA 1.40 ± 0.28 0.81 ± 0.16 1.29 ± 0.18 0.64 ± 0.16
DOPAC+HVA/DA 0.74 ± 0.23 0.96 ± 0.13 1.02 ± 0.16 0.86 ± 0.22
NA 0.12 ± 0.03 0.12 ± 0.03 0.12 ± 0.02 0.12 ± 0.02
5HT 0.07 ± 0.02 0.06 ± 0.01 0.06 ± 0.01 0.13 ± 0.03
5HIAA/5HT 0.63 ± 0.08 0.99 ± 0.17 0.68 ± 0.06 0.42 ± 0.08
CPu
DA 2.56 ± 0.52 2.74 ± 0.64 2.34 ± 0.36 2.18 ± 0.52
DOPAC+HVA/DA 0.59 ± 0.14 0.65 ± 0.14 0.69 ± 0.08 0.48 ± 0.06
NA 0.07 ± 0.01 0.10 ± 0.01 0.10 ± 0.01 0.14 ± 0.01
5HT 0.15 ± 0.02 0.11 ± 0.02 0.12 ± 0.02 0.12 ± 0.02
5HIAA/5HT 2.43 ± 0.51 3.21 ± 0.62 2.87 ± 0.65 2.77 ± 0.76
HYPO
DA 0.28 ± 0.03 0.39 ± 0.11 0.25 ± 0.06 0.35 ± 0.03
DOPAC+HVA/DA 0.52 ± 0.10 0.48 ± 0.06 0.50 ± 0.07 0.36 ± 0.05
NA 0.90 ± 0.07 1.45 ± 0.11 1.06 ± 0.14 1.56 ± 0.21
5HT 0.24 ± 0.03 0.32 ± 0.04 0.44 ± 0.06 0.59 ± 0.07
5HIAA/5HT 3.13 ± 0.61 2.30 ± 0.88 2.17 ± 0.24 1.23 ± 0.18
AMY
DA 0.40 ± 0.13 0.43 ± 0.07 0.59 ± 0.24 0.36 ± 0.09
DOPAC+HVA/DA 0.59 ± 0.09 0.46 ± 0.08 0.92 ± 0.16 0.47 ± 0.07
NA 0.24 ± 0.05 0.23 ± 0.04 0.28 ± 0.08 0.19 ± 0.03
5HT 0.10 ± 0.03 0.16 ± 0.04 0.07 ± 0.02 0.10 ± 0.03
5HIAA/5HT 0.94 ± 0.41 1.39 ± 0.36 3.16 ± 1.22 1.16 ± 0.37
HIPP
DA 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01
DOPAC+HVA/DA 3.11 ± 0.75 3.86 ± 1.06 3.67 ± 1.00 2.88 ± 0.84
NA 0.22 ± 0.04 0.20 ± 0.02 0.23 ± 0.04 0.27 ± 0.03
5HT 0.11 ± 0.02 0.12 ± 0.03 0.09 ± 0.02 0.22 ± 0.05
5HIAA/5HT 4.27 ± 0.73 3.85 ± 0.51 4.83 ± 0.75 4.08 ± 0.42
SN
DA 0.18 ± 0.03 0.17 ± 0.03 0.13 ± 0.03 0.15 ± 0.01
DOPAC+HVA/DA 0.93 ± 0.09 0.94 ± 0.07 1.07 ± 0.10 0.73 ± 0.10
NA 0.17 ± 0.03 0.23 ± 0.05 0.19 ± 0.03 0.24 ± 0.02
5HT 0.19 ± 0.05 0.26 ± 0.07 0.14 ± 0.04 0.24 ± 0.03
5HIAA/5HT 3.11 ± 0.90 3.60 ± 0.86 2.90 ± 0.55 1.30 ± 0.21
VTA
DA 0.17 ± 0.02 0.34 ± 0.07 0.18 ± 0.03 0.34 ± 0.06
DOPAC+HVA/DA 0.90 ± 0.11 0.79 ± 0.09 0.95 ± 0.08 0.73 ± 0.08
NA 0.24 ± 0.02 0.28 ± 0.07 0.20 ± 0.03 0.34 ± 0.03
5HT 0.13 ± 0.02 0.16 ± 0.04 0.11 ± 0.02 0.24 ± 0.04
5HIAA/5HT 1.78 ± 0.59 1.92 ± 0.47 1.72 ± 0.41 1.43 ± 0.29
DR
DA 0.05 ± 0.01 0.09 ± 0.01 0.07 ± 0.01 0.09 ± 0.03
DOPAC+HVA/DA 0.31 ± 0.04 0.17 ± 0.03 0.33 ± 0.08 0.33 ± 0.06
NA 0.15 ± 0.02 0.21 ± 0.02 0.18 ± 0.05 0.19 ± 0.05
5HT 0.04 ± 0.01 0.08 ± 0.01 0.11 ± 0.03 0.19 ± 0.06
5HIAA/5HT 1.07 ± 0.47 1.30 ± 0.68 1.67 ± 0.74 1.13 ± 0.43
LC
DA 0.07 ± 0.01 0.08 ± 0.01 0.06 ± 0.01 0.10 ± 0.01
DOPAC+HVA/DA 0.87 ± 0.14 0.71 ± 0.16 0.64 ± 0.06 0.70 ± 0.08
NA 0.32 ± 0.06 0.29 ± 0.07 0.22 ± 0.05 0.40 ± 0.05
5HT 0.07 ± 0.03 0.10 ± 0.04 0.06 ± 0.01 0.16 ± 0.04
5HIAA/5HT 2.76 ± 0.95 2.41 ± 0.37 2.63 ± 0.34 2.98 ± 0.53
**
***
*
*
°
*
*
*
*
*
°
*
**
*
°
°
*
**
*
*
*
*
*
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in situ hybridization in the brains of NR+ S and R+ S rats treated
with either OEA or vehicle and sacrificed at the end of the stress
exposure (Fig. 1b, EXP. 4).
As shown in the representative autoradiography reported in
Fig. 3c, e, CRF mRNA signal was detected and measured in the CeA
and the PVN. The results of the densitometric analyses of CeA
were statistically analyzed by two-way ANOVA that revealed no
effect of caloric restriction and no effect of treatment, but a
significant interaction between the two factors (Finteraction= 9.491,
df= 1/19, P < 0.01). Post hoc analyses demonstrated that OEA
treatment reduced CRF mRNA in the CeA of bingeing rats (Fig. 3d),
whereas the two-way ANOVA in the PVN revealed no significant
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effect (Fig. 3f). As shown in the representative autoradiography
reported in Fig. 3g oxytocin mRNA signal was detected and
measured in the PVN. Two-way ANOVA analyses revealed a
significant effect of food restriction (Frestriction= 9.897, df= 1/20,
P < 0.01), no effect of treatment, and a significant interaction
between the two factors (Finteraction= 5.544, df= 1/20, P < 0.05).
The post hoc analyses demonstrated that oxytocin mRNA
expression was significantly increased in bingeing rats treated
with OEA (Fig. 3h).
OEA treatment affected oxytocin receptor expression in selected
brain areas of bingeing rats
Oxytocin receptors are abundantly expressed in the striatum [60],
where they control, through different mechanisms, dopaminergic
neurotransmission. Therefore, as the last step of our study, we
investigated whether bingeing rats show different oxytocin
receptor immunoreactivity in the CPu and Acb (Fig. 3i, k), as
compared with non-bingeing rats, and whether OEA treatment
might affect such parameters. The results obtained by the
semiquantitative densitometric analyses of optical densities
revealed that binge eating behavior in R+ S rats was associated
with a reduced oxytocin receptor expression within both the
dorsal (CPu) and the ventral (Acb) striatum, and that OEA
treatment completely restored such decrease, reporting oxytocin
receptor immunoreactivity to the level observed in NR+ S rats
(Fig. 3j, l). In particular, two-way ANOVA analyses of oxytocin
receptor expression within the Acb revealed a significant effect of
treatment (Ftreatment= 7.445, df= 1/11, P < 0.05), no effect of food
restriction, and significant interaction between the two factors
(Finteraction= 6.363, df= 1/11, P < 0.05). The same effect was
observed within the CPu (Finteraction= 8.479, df= 1/11, P < 0.05)
(Fig. 3j, l).
DISCUSSION
OEA prevents binge-like palatable food consumption
This study demonstrates that OEA prevents binge-like palatable
food consumption induced by stress in female rats with a history
of food restriction (R+ S rats), supporting the hypothesis that this
lipid signal might represent a potential target for the development
of more efficacious and safer treatments for BED or for other
eating disorders characterized by binge episodes. The effect of
OEA was dose- and time-dependent, being long-lasting at the
dose of 10 mg kg−1 i.p. According to previous reports from our
laboratory and from other research groups [25–27, 29, 30], this
dosage of OEA is able to induce satiety in both free-feeding and
food-deprived rats, without causing motor impairment, malaise,
pain, or hormonal and body temperature alterations. In the
present study, we were unable to detect any significant effect of
OEA on feeding behavior in the other three experimental groups,
which did not show binge-like palatable food intake within the
timeframe of the experiment. This observation suggests that the
anti-binge effects of OEA, rather than the expression of satiety
induction, might likely be the consequence of the selective
inhibition of “hedonic hunger” [61, 62].
OEA modulates monoaminergic tone in key brain areas
Based on this evidence, to investigate the neurobiological
counterparts of OEA effect on binge eating, we focused our
attention on the so-called “DA motive system” controlling the
reinforcement and motivational aspects of feeding, including
compulsive eating [63]. Our choice is based on previous findings
demonstrating the capability of OEA to counteract different
addiction-related behaviors, by acting within this system [64–66].
The results obtained by analyzing c-Fos expression in brain
areas that partake directly or indirectly to this system suggest that
the anti-binge effects of OEA are associated with its ability to
dampen the “trigger” effects of stress in R+ S rats. This action is
accomplished by “normalizing” the activity of areas responding to
stress exposure (Acb, CPu, SN, and AMY), and by increasing the
activation of areas involved in the control of food intake (VTA and
PVN). The effect observed in the Acb was associated with a
decrease of DA tissue levels induced by OEA administration to R
+ S rats. Expanding this latter result, data obtained from
microdialysis of the AcbSh revealed that OEA dampened DA
response to stress and to amphetamine challenge in both R+ S
and NR+ S rats. Previous studies from Tellez and collaborators
have demonstrated that OEA treatment restored a normal
dopaminergic nigrostriatal response to fat intake in diet-induced
obese mice [33]. The results of our experiments expand their
observation, demonstrating that OEA is able to restore a normal
dopaminergic response not only to food consumption but also to
stress-induced appetitive motivation. However, in our study, the
attenuation of AcbSh DA release evoked by OEA in response to
stress exposure did not perfectly parallel the selective behavioral
effects. In fact, although OEA induced the same effect on DA
release in the Acb of both R+ S and NR+ S rats, it significantly
inhibited HPF consumption only in the R+ S group, thus
suggesting the involvement of other possible systems.
Based on previous observations, we hypothesized that these
systems might include 5-HT, NA, CRF, and oxytocin. In support of
this hypothesis, we found that in R+ S rats, OEA selectively
Fig. 3 OEA treatment dampened AcbSh DA release induced by stress exposure or amphetamine challenge. OEA treatment affected CRF,
oxytocin mRNA levels, and oxytocin receptor expression in bingeing rats. Time course of extracellular DA levels (expressed as % of basal
values) measured in the nucleus accumbens shell of NR+ S (non restricted+ stressed, a, N= 9–11) and R+ S (restricted+ stressed, b, N= 6–9)
rats during microdialysis experiment. The first three samples were collected before treating rats with vehicle (veh) or OEA (10mg kg−1, i.p.)
and used as baseline (NR+ S baseline= 225.5 ± 43.66; R+ S baseline= 205.1 ± 21.07, no statistically significant difference); 45 min after
treatment, rats were subjected to the stress procedure for 15min and subsequently received the HPF for 60min. Thirty minutes after the end
of HPF exposure, rats were administered with amphetamine (0.5 mg kg−1, subcutaneous injection (s.c.)). Data are expressed as mean ± SEM. *P
< 0.05; **P < 0.01; ***P < 0.001 vs the mean of the first three samples (basal values) within the same group (Dunnett’s multiple-comparison
test). °P < 0.05; °°P < 0.01; °°°P < 0.001 vs OEA-treated rats in the same time point of the same diet regimen group (Bonferroni’s test for between-
group comparisons). Red arrow: veh or OEA (10mg kg−1, i.p.) administration; blue arrow: amphetamine administration (0.5 mg kg−1, s.c.).
Representative in situ hybridization images (scale bar= 1mm) of CRF mRNA expression within the central amygdala (CeA, c), CRF, and
oxytocin mRNA in the paraventricular nucleus (PVN, e, g) of NR+ S (non restricted+ stressed) and R+ S (restricted+ stressed) rats treated
with either vehicle (veh) or OEA (10mg kg−1, i.p.), and sacrificed 60min after the treatment. Semiquantitative densitometric analyses of CRF
mRNA in the CeA (d), and CRF and oxytocin mRNA in the PVN (f, h, respectively) of NR+ S and R+ S rats treated with either veh or OEA
(10mg kg−1, i.p.), and sacrificed 60min after treatment. Data are expressed as mean ± SEM. *P < 0.05 vs veh in the same diet regimen
group (Tukey’s post hoc test, N= 4–6). Representative photomicrographs (scale bar= 500 μm) showing oxytocin receptor (OXTR)
immunostaining within the nucleus accumbens (core and shell, i) and the caudate putamen (k) in brain slices collected from both NR+ S
(non restricted+ stressed) and R+ S (restricted+ stressed) rats treated with either vehicle (veh) or OEA (10 mg kg−1, i.p.) and sacrificed
120min after treatment. Semiquantitative densitometric analysis of oxytocin receptor expression within the nucleus accumbens (j) and
caudate putamen (l) of NR+ S and R+ S rats treated with either veh or OEA (10mg kg−1, i.p.) and sacrificed 120min after treatment. Data are
expressed as mean ± SEM. **P < 0.01; ***P < 0.001 vs veh in the same diet regimen group; °P < 0.05; °°P < 0.01 vs NR+ S in the same treatment
group (Tukey’s post hoc test, N= 3).
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enhanced NA levels in the CPu, VTA, and LC, as well as it increased
5-HT tissue levels in most of the brain areas analyzed (mPFC, Acb,
HIPP, VTA, and LC). These results are in accordance with previous
studies showing that OEA exerts anti-depressant-like effects in
different animal models [34], by regulating 5-HT and NA levels
[36], and suggest that the anti-binge effects of OEA might
occur, at least in part, by promoting a high serotonergic/
noradrenergic tone.
OEA affects central CRF and oxytocinergic systems in bingeing rats
The results obtained within the AMY, where OEA significantly
decreased stress-induced c-Fos activation in bingeing rats,
prompted us to investigate whether OEA might influence the
CRF system, known to coordinate the frustration-stress response
in a rat model [48]. In agreement with this notion, and
overlapping with the trend of c-Fos induction in the AMY, we
found that OEA decreased CRF mRNA level in the CeA of R+ S
rats, without producing any effect on the PVN, and without
affecting the same parameters in NR+ S rats. The results confirm
previous findings demonstrating that hypothalamic CRF system
is not sufficient to account for binge-like HPF consumption in our
BED model [47, 48], and that CRF in the CeA plays a key role in
other models of excessive palatable food consumption [67–69].
These latter observations were further supported by the findings
that treatments with CRF antagonists can prevent binge eating
by interacting with CRF receptors in bed nucleus of the stria
terminalis [47, 48, 70] and CeA [67–69], rather than at
hypothalamic levels.
Furthermore, we hypothesized that the ability of OEA to
increase c-Fos expression within the PVN of R+ S rats might be
linked to the activation of oxytocinergic neurons [30]. In
agreement with our previous studies [29, 32], we found that
OEA treatment increased oxytocin mRNA levels in the PVN of R+
S rats, without producing any effect on NR+ S rats. We expanded
this notion by analyzing also oxytocin receptor expression. We
observed a reduced immunoreactivity for oxytocin receptors
within both the CPu and the Acb of R+ S rats, as compared with
NR+ S rats. This result suggests a hypofunctionality of the
oxytocinergic system at the level of these two brain regions that
might be associated with the compulsive eating in response to
stress. In fact, it is well demonstrated that oxytocin transmission
has a key role in attenuating stress responses by exerting
inhibitory actions on the HPA axis, sympathetic activity, and
anxiety-related behavior during exposure to stressful stimuli [71–
73]. Our functional hypothesis is that cycles of food restriction
might attenuate oxytocin sensitivity in R+ S rats; OEA treatment
might be able to rescue this alteration by normalizing oxytocin
receptor density and stimulating oxytocin release from the PVN,
thus overall increasing oxytocin transmission in bingeing rats.
Such effect might contribute, in turn, to the reduced CRF synthesis
in the CeA, as supported by several findings demonstrating a
genomic effect of oxytocin on CRF gene expression [74].
CONCLUSIONS
We provide evidence that OEA exerts a selective inhibitory effect
on binge-like eating behavior in female rats, and that such effect is
associated with the modulation of several neurochemical end-
points measured within the hedonic–homeostatic circuits that
involve monoaminergic systems, as well as two key neuropepti-
dergic systems, namely CRF and oxytocin. Although further
studies should investigate the causative link between these
observations, our findings broaden the current knowledge of
the role played by OEA in the caloric–homeostatic control system,
and support the hypothesis that OEA might represent a novel
potential pharmacological target for the treatment of aberrant
eating patterns.
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